Symphogen and Cambridge Antibody Technology sign patent licensing agreement

30-Aug-2005

Symphogen A/S announced that it has entered into a patent license agreement with Cambridge Antibody Technology. Under the terms of the agreement, Symphogen receives a license to use CAT's antibody phage display patents for research purposes and to develop and commercialize a number of therapeutic and diagnostic antibody products. Upon signing the agreement, Symphogen made an upfront payment for the license and exercised its first product license option to develop and commercialize its lead product Sym001. As a condition of exercising this option, Symphogen paid a product license fee and may make future milestone and royalty payments to CAT.

Sym001 is a recombinant, fully human, anti Rhesus D polyclonal antibody which Symphogen is developing for Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of Newborns (HDN). The Company plans to file an IND for initiation of Phase I clinical trials in 2006.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...